Thoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 study.

Zhang, Jing; Ren, Yue; Wang, Qiu; Jia, Yu-Ming

Zhang, Jing; Ren, Yue; Wang, Qiu; Jia, Yu-Ming.

Afiliación

Zhang J; Department of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, China.
Ren Y; Department of Oncology, Yangzhou University, No. 136, Jiangyang Middle Road, Yangzhou, 225002, Jiangsu Province, China.
Wang Q; Department of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, China.
Jia YM; Department of Oncology, The Second People's Hospital of Yibin, No. 268, Nanguang Road, Yibin, 644000, Sichuan Province, China.

Future Oncol ; 18(7): 751-753, 2022 03.

Article en En | MEDLINE | ID: mdl-35048746

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Humanos; Quinazolinonas

Palabras clave

adverse reactions; dacomitinib; efficacy; pharmacokinetics; plasma exposure concentration; side effects

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google